- Home
- ADIL vs ONVO Comparison
ADIL vs ONVO Comparison
Compare ADIL & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- ONVO
- Stock Information
- Founded
- ADIL 2010
- ONVO 2007
- Country
- ADIL United States
- ONVO United States
- Employees
- ADIL N/A
- ONVO N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADIL Health Care
- ONVO Health Care
- Exchange
- ADIL Nasdaq
- ONVO Nasdaq
- Market Cap
- ADIL 4.8M
- ONVO 5.3M
- IPO Year
- ADIL 2018
- ONVO N/A
- Fundamental
- Price
- ADIL $0.79
- ONVO $0.37
- Analyst Decision
- ADIL Strong Buy
- ONVO
- Analyst Count
- ADIL 1
- ONVO 0
- Target Price
- ADIL $8.00
- ONVO N/A
- AVG Volume (30 Days)
- ADIL 172.8K
- ONVO 103.2K
- Earning Date
- ADIL 03-31-2025
- ONVO 02-19-2025
- Dividend Yield
- ADIL N/A
- ONVO N/A
- EPS Growth
- ADIL N/A
- ONVO N/A
- EPS
- ADIL N/A
- ONVO N/A
- Revenue
- ADIL N/A
- ONVO $122,000.00
- Revenue This Year
- ADIL N/A
- ONVO $59.08
- Revenue Next Year
- ADIL N/A
- ONVO $18.24
- P/E Ratio
- ADIL N/A
- ONVO N/A
- Revenue Growth
- ADIL N/A
- ONVO N/A
- 52 Week Low
- ADIL $0.72
- ONVO $0.32
- 52 Week High
- ADIL $4.17
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- ADIL 40.52
- ONVO 49.60
- Support Level
- ADIL $0.76
- ONVO $0.33
- Resistance Level
- ADIL $0.85
- ONVO $0.40
- Average True Range (ATR)
- ADIL 0.05
- ONVO 0.03
- MACD
- ADIL 0.01
- ONVO 0.00
- Stochastic Oscillator
- ADIL 50.77
- ONVO 61.25
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.